These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 32037829)

  • 1. Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib.
    Bagnolini G; Milano D; Manerba M; Schipani F; Ortega JA; Gioia D; Falchi F; Balboni A; Farabegoli F; De Franco F; Robertson J; Pellicciari R; Pallavicini I; Peri S; Minucci S; Girotto S; Di Stefano G; Roberti M; Cavalli A
    J Med Chem; 2020 Mar; 63(5):2588-2619. PubMed ID: 32037829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells.
    Roberti M; Schipani F; Bagnolini G; Milano D; Giacomini E; Falchi F; Balboni A; Manerba M; Farabegoli F; De Franco F; Robertson J; Minucci S; Pallavicini I; Di Stefano G; Girotto S; Pellicciari R; Cavalli A
    Eur J Med Chem; 2019 Mar; 165():80-92. PubMed ID: 30660828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors.
    Falchi F; Giacomini E; Masini T; Boutard N; Di Ianni L; Manerba M; Farabegoli F; Rossini L; Robertson J; Minucci S; Pallavicini I; Di Stefano G; Roberti M; Pellicciari R; Cavalli A
    ACS Chem Biol; 2017 Oct; 12(10):2491-2497. PubMed ID: 28841282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An
    Myers SH; Poppi L; Rinaldi F; Veronesi M; Ciamarone A; Previtali V; Bagnolini G; Schipani F; Ortega Martínez JA; Girotto S; Di Stefano G; Farabegoli F; Walsh N; De Franco F; Roberti M; Cavalli A
    Eur J Med Chem; 2024 Feb; 265():116114. PubMed ID: 38194775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
    Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC.
    Sun C; Cao W; Qiu C; Li C; Dongol S; Zhang Z; Dong R; Song K; Yang X; Zhang Q; Kong B
    J Hematol Oncol; 2020 Jan; 13(1):9. PubMed ID: 32005272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
    Liu FW; Tewari KS
    Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resurrection of PARP Inhibitors in Breast Cancer.
    Lyons TG; Robson ME
    J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.
    Ji W; Weng X; Xu D; Cai S; Lou H; Ding L
    Biochem Biophys Res Commun; 2020 Jan; 522(1):121-126. PubMed ID: 31753490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
    Zatreanu D; Robinson HMR; Alkhatib O; Boursier M; Finch H; Geo L; Grande D; Grinkevich V; Heald RA; Langdon S; Majithiya J; McWhirter C; Martin NMB; Moore S; Neves J; Rajendra E; Ranzani M; Schaedler T; Stockley M; Wiggins K; Brough R; Sridhar S; Gulati A; Shao N; Badder LM; Novo D; Knight EG; Marlow R; Haider S; Callen E; Hewitt G; Schimmel J; Prevo R; Alli C; Ferdinand A; Bell C; Blencowe P; Bot C; Calder M; Charles M; Curry J; Ekwuru T; Ewings K; Krajewski W; MacDonald E; McCarron H; Pang L; Pedder C; Rigoreau L; Swarbrick M; Wheatley E; Willis S; Wong AC; Nussenzweig A; Tijsterman M; Tutt A; Boulton SJ; Higgins GS; Pettitt SJ; Smith GCM; Lord CJ
    Nat Commun; 2021 Jun; 12(1):3636. PubMed ID: 34140467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The F-Box Domain-Dependent Activity of EMI1 Regulates PARPi Sensitivity in Triple-Negative Breast Cancers.
    Marzio A; Puccini J; Kwon Y; Maverakis NK; Arbini A; Sung P; Bar-Sagi D; Pagano M
    Mol Cell; 2019 Jan; 73(2):224-237.e6. PubMed ID: 30554948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors.
    Jdey W; Thierry S; Russo C; Devun F; Al Abo M; Noguiez-Hellin P; Sun JS; Barillot E; Zinovyev A; Kuperstein I; Pommier Y; Dutreix M
    Clin Cancer Res; 2017 Feb; 23(4):1001-1011. PubMed ID: 27559053
    [No Abstract]   [Full Text] [Related]  

  • 13. Dual PARP and RAD51 Inhibitory Drug Conjugates Show Synergistic and Selective Effects on Breast Cancer Cells.
    Malka MM; Eberle J; Niedermayer K; Zlotos DP; Wiesmüller L
    Biomolecules; 2021 Jul; 11(7):. PubMed ID: 34356606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Short BRCA2-Derived Cell-Penetrating Peptide Targets RAD51 Function and Confers Hypersensitivity toward PARP Inhibition.
    Trenner A; Godau J; Sartori AA
    Mol Cancer Ther; 2018 Jul; 17(7):1392-1404. PubMed ID: 29654063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel UCHL
    Song Z; Tu X; Zhou Q; Huang J; Chen Y; Liu J; Lee S; Kim W; Nowsheen S; Luo K; Yuan J; Lou Z
    Cell Death Dis; 2019 May; 10(6):398. PubMed ID: 31113933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New RAD51 Inhibitors to Target Homologous Recombination in Human Cells.
    Shkundina IS; Gall AA; Dick A; Cocklin S; Mazin AV
    Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34208492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.
    Barber LJ; Sandhu S; Chen L; Campbell J; Kozarewa I; Fenwick K; Assiotis I; Rodrigues DN; Reis Filho JS; Moreno V; Mateo J; Molife LR; De Bono J; Kaye S; Lord CJ; Ashworth A
    J Pathol; 2013 Feb; 229(3):422-9. PubMed ID: 23165508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.
    Shen YT; Evans JC; Zafarana G; Allen C; Piquette-Miller M
    Mol Pharm; 2018 Jul; 15(7):2742-2753. PubMed ID: 29750868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts.
    Guffanti F; Alvisi MF; Anastasia A; Ricci F; Chiappa M; Llop-Guevara A; Serra V; Fruscio R; Degasperi A; Nik-Zainal S; Bani MR; Lupia M; Giavazzi R; Rulli E; Damia G
    Br J Cancer; 2022 Jan; 126(1):120-128. PubMed ID: 34732853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
    Carey JPW; Karakas C; Bui T; Chen X; Vijayaraghavan S; Zhao Y; Wang J; Mikule K; Litton JK; Hunt KK; Keyomarsi K
    Cancer Res; 2018 Feb; 78(3):742-757. PubMed ID: 29180466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.